Jan 6, 2015 · BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients …

Mission. Build the first next-generation oncology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and …

2 DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. 3 Leads Biolabs collaboration; BeiGene has global research, development, and …

Clare Fisher joined BeiGene in 2021 as Senior Vice President, Business Development and Mergers & Acquisitions (ex-China), bringing more than two decades of healthcare experience …

BeiGene seeks to develop and deliver impactful medicines to more patients around the world. The products shown here may not be available in all countries or regions. Please visit your local …

In 2023, BeiGene laid the foundation to become a leader in global health equity. We developed a vision and mission for this commitment that reflects the voices and needs of at-risk patients, …

BeiGene is a publicly traded global oncology company. BeiGene had its IPO on the NASDAQ in February 2016, and is currently traded on the NASDAQ, the Hong Kong Stock Exchange, and …

The power button within the last “e” represents our always “on” approach in pursuing novel medicines that turn cancer “off” by disrupting key drivers of cancer cell growth and survival, …

Lot 4-401 & 4-402, Level 4, The Starling Mall No, 6, Jalan SS 21/37, Damansara Utama, 47400 Petaling Jaya, Selangor, Malaysia

Jul 23, 2024 · BeiGene’s $800 million investment is the culmination of a three-year project to expand the Company’s integrated manufacturing and research and development footprint in …